- $3.36m
- -$14.29m
- 29
- 50
- 13
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.5 | ||
| Price to Tang. Book | 0.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -58.44% | ||
| Return on Equity | -83.8% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The Company is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Directors
- Joshua Silverman NEC (50)
- Daniel Alkon PRE (78)
- Alan Tuchman CEO (74)
- William Singer VCH (80)
- Robert Weinstein CFO (61)
- Bruce Bernstein IND (57)
- Jonathan Schechter IND (47)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 31st, 2012
- Public Since
- December 7th, 2020
- No. of Shareholders
- 362
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 1,389,815
- Address
- 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, 10036
- Web
- https://www.synaptogen.com/
- Phone
- +1 9732420005
- Auditors
- Morison Cogen, LLP
Upcoming Events for SNPX
Similar to SNPX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 23:33 UTC, shares in Synaptogenix are trading at $2.42. This share price information is delayed by 15 minutes.
Shares in Synaptogenix last closed at $2.42 and the price had moved by -49.16% over the past 365 days. In terms of relative price strength the Synaptogenix share price has underperformed the S&P500 Index by -54.16% over the past year.
The overall consensus recommendation for Synaptogenix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSynaptogenix does not currently pay a dividend.
Synaptogenix does not currently pay a dividend.
Synaptogenix does not currently pay a dividend.
To buy shares in Synaptogenix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.42, shares in Synaptogenix had a market capitalisation of $3.36m.
Here are the trading details for Synaptogenix:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SNPX
Based on an overall assessment of its quality, value and momentum Synaptogenix is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Synaptogenix is $14.00. That is 478.51% above the last closing price of $2.42.
Analysts covering Synaptogenix currently have a consensus Earnings Per Share (EPS) forecast of -$8.54 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Synaptogenix. Over the past six months, its share price has underperformed the S&P500 Index by -17.87%.
As of the last closing price of $2.42, shares in Synaptogenix were trading -21.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Synaptogenix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Synaptogenix's management team is headed by:
- Joshua Silverman - NEC
- Daniel Alkon - PRE
- Alan Tuchman - CEO
- William Singer - VCH
- Robert Weinstein - CFO
- Bruce Bernstein - IND
- Jonathan Schechter - IND